News Insights 10 July 2025

Deutsche Numis has been appointed as joint
corporate broker to HUTCHMED (China) Limited

Med-ArticleBanner-1100x595

We have been appointed as joint corporate broker to HUTCHMED (China) Limited, a c.£2.0bn market cap business headquartered in Hong Kong and listed on AIM, Nasdaq and HKEX.


HUTCHMED is an innovative biopharma company focused on the discovery, development and commercialisation of targeted therapies for oncology and immunological diseases. It generated $630m of revenue in 2024, and is one of the largest companies trading on AIM.

We are thrilled to have been appointed by HUTCHMED, a leading biopharma innovator based in China with a proven track record of in-house drug discovery, development and global commercialisation. We look forward to supporting the HUTCHMED team in delivering their growth ambitions. Freddie Barnfield, Head of Healthcare, at Deutsche Numis.